Your browser doesn't support javascript.
loading
Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces.
Lee, Myungjin; Changela, Anita; Gorman, Jason; Rawi, Reda; Bylund, Tatsiana; Chao, Cara W; Lin, Bob C; Louder, Mark K; Olia, Adam S; Zhang, Baoshan; Doria-Rose, Nicole A; Zolla-Pazner, Susan; Shapiro, Lawrence; Chuang, Gwo-Yu; Kwong, Peter D.
Afiliação
  • Lee M; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Changela A; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Gorman J; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Rawi R; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Bylund T; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Chao CW; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Lin BC; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Louder MK; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Olia AS; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Zhang B; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Doria-Rose NA; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Zolla-Pazner S; Department of Medicine and Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Shapiro L; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Chuang GY; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, 10032, USA.
  • Kwong PD; Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, 20892, USA. gwo-yu.chuang@nih.gov.
Nat Commun ; 12(1): 6470, 2021 11 09.
Article em En | MEDLINE | ID: mdl-34753907
ABSTRACT
Antibody-Framework-to-Antigen Distance (AFAD) - the distance between the body of an antibody and a protein antigen - is an important parameter governing antibody recognition. Here, we quantify AFAD for ~2,000 non-redundant antibody-protein-antigen complexes in the Protein Data Bank. AFADs showed a gaussian distribution with mean of 16.3 Å and standard deviation (σ) of 2.4 Å. Notably, antibody-antigen complexes with extended AFADs (>3σ) were exclusively human immunodeficiency virus-type 1 (HIV-1)-neutralizing antibodies. High correlation (R2 = 0.8110) was observed between AFADs and glycan coverage, as assessed by molecular dynamics simulations of the HIV-1-envelope trimer. Especially long AFADs were observed for antibodies targeting the glycosylated trimer apex, and we tested the impact of introducing an apex-glycan hole (N160K); the cryo-EM structure of the glycan hole-targeting HIV-1-neutralizing antibody 2909 in complex with an N160K-envelope trimer revealed a substantially shorter AFAD. Overall, extended AFADs exclusively recognized densely glycosylated surfaces, with the introduction of a glycan hole enabling closer recognition.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Anticorpos Amplamente Neutralizantes / Complexo Antígeno-Anticorpo Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Anticorpos Amplamente Neutralizantes / Complexo Antígeno-Anticorpo Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article